Oral vitamin B12 to improve aromatase inhibitors (AI)-associated musculoskeletal symptoms (AIMSS).

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e21679-e21679
Author(s):  
Aleli Campbell ◽  
Zeina A. Nahleh ◽  
Rosalinda Heydarian ◽  
Cecilia Ochoa ◽  
Alok Dwivedi
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Vitamin B12 ◽  
Joint Pain ◽  
Musculoskeletal Symptoms ◽  
P Value ◽  
Pain Scores ◽  
End Of Treatment ◽  
Pain Improvement

e21679 Background: Breast cancer patients undergoing Aromatase Inhibitor (AI) therapy often experience many side effects, which include musculoskeletal and joint pain. Vitamin B12 has often been used as a naturopathic supplement to relieve joint pain that is caused by arthritis. The purpose of this study was to evaluate the effect of Vitamin B12 supplements on musculoskeletal pain and arthralgias induced by aromatase inhibitors (AI) therapy. Methods: After approval by Institutional Review Board (IRB), we enrolled consecutive patients treated at the Texas Tech Breast Care Center who had a diagnosis of invasive breast cancer, Stages I-III, and were taking an AI and experiencing significant musculoskeletal symptoms assessed by the Brief Pain Inventory-Short Form (BPI-SF) questionnaire. Participants received 2500 mcg of sublingual vitamin B12 daily for 90 days. Assessments included improvement in BPI-SF pain scores at 3 months, the impact on quality of life determined by the Functional Assessment of Cancer Therapy–Endocrine Symptoms, FACT-ES and correlative serum markers. Results: A total of forty-one patients were enrolled, five patients withdrew, leaving thirty-six patients to complete the study. Analysis of the data collected indicate a 34% average pain improvement (P-value = 0.0001) as reported by patients at baseline and at the end of treatment in the BPI-SF questionnaire. Additionally, a 23 % worst pain improvement (P-value = 0.0003) was obtained for worst pain scores evaluated similarly, at baseline and at the end of treatment. Analysis of the results for the FACT-ES scoring showed improvement on all scales. No significant adverse events were observed. Additionally, decrease in pain score was correlated with increased serum B12 levels. A paired t-test was used to assess the mean difference between baseline and endpoint. Conclusions: This study suggests that vitamin B12 reduces pain and improves quality of life for patients taking AIs who experienced AI-related musculoskeletal symptoms. If confirmed in large randomized prospective trials, Vitamin B12 would be a safe and cost effective option for the treatment of AI -related musculoskeletal symptoms.

scholarly journals Hubungan Dukungan Keluarga Terhadap Kualitas Hidup Pasien Kanker Payudara di Rumah Sakit Islam Siti Khodijah Palembang Tahun 2018

2019 ◽  
Vol 19 (3) ◽  
pp. 529
Author(s):  
Yofa Anggriani Utama
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Developing Countries ◽  
Family Support ◽  
Cancer Patients ◽  
Sampling Technique ◽  
P Value ◽  
Breast Cancer Patients ◽  
The World

Cancer is one of the causes of death in both developed and developing countries, cancer is increasing in developing countries due to increasing lifestyle, breast cancer is a cancer that causes death in women in the world, breast cancer is the highest contributor to mortality in women in the world, 43.3 per 100,000. The purpose of this study was to determine the relationship of family support to the quality of life of breast cancer patients. The research design used was observational analytic with cross sectional approach. The sampling technique used purposive sampling technique, the study sample amounted to 63 breast cancer patients. The results show that there is a relationship between family support and the quality of life of breast cancer patients with a p value of 0.032. shows there is a relationship between family support for the quality of life of patients with breast cancer. Suggestions that nurses can improve the quality of nursing services, and provide motivation to patients and families of breast cancer in carrying out breast cancer treatment.

scholarly journals Social support and quality of life among female breast cancer patients at Tikur Anbessa Specialized Hospital, Ethiopia 2019:Cross-sectional study

2020 ◽  
Author(s):  
Rahel Aberaraw ◽  
Jemal Hussien ◽  
Abdisa Boka ◽  
Roza Teshome ◽  
Addisu Yeshambel
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Social Support ◽  
Cancer Patients ◽  
Female Breast Cancer ◽  
P Value ◽  
Breast Cancer Patients ◽  
Female Breast ◽  
Specialized Hospital

Abstract Background Breast cancer is a major life-threatening public health problem worlwide. It is the most common form of cancer among women in many developing countries including Ethiopia. Social support could change the course of cancer and can influence the quality of life among breast cancer patients. Therefore, purpose of this study was to assess social support and quality of life among female breast cancer patients attending in Tikur Anbassa Specialized Hospital, Addis Ababa, Ethiopia 2019.Methods A Hospital-based cross-sectional study was conducted in Tikur Anbessa Specialized Hospital, Ethiopia from March to April 2019. A total of 214 female breast cancer patients were included and a systematic sampling method was used. A structured and pre-tested questionnaire was used. Data entry was done using epi data manager version 4.2. Data analysis was done using Statistical Package for Social Sciences version 25. Binary and multiple logistic regression was used to show the association of social support and quality of life. Variables significantly associated were declared at P-value <0.05 and 95%CI was used.Result A total of 214 women with breast cancer were recruited. Of the total participants, 124(58%) had good social support. It was found that participants who were college graduated (AOR=3, 95%CI: 1.5, 5.9 COR=3.2) and who had high monthly income(AOR=2.3, 95% CI: 1.2,8.5, COR= 5.39) were more likely to have good social support. It was also found that participants who were illiterate (AOR=3, 95%CI: 1.3,6.9, COR=4.8, p-value=0.008), who had systematic therapy side effects(AOR=3.8, 95%CI: 1.1,13, COR=4, p-value=0.035)and participants who had problem of appetite loss(AOR=3.5, 95%CI: 1.02,12COR=4, p-value= 0.047) were more likely to have affected QoL. Conclusion In this study finding, social support and, quality of life in breast cancer patients was low. Healthcare providers should enhance social support which may help to improve the quality of life of women with breast cancer.

scholarly journals Hubungan Lama Menjalani Kemoterapi Dengan Kualitas Hidup Penderita Kanker Payudara Di RSUD Ulin Banjarmasin

2020 ◽  
Vol 10 (1) ◽  
pp. 253-265
Author(s):  
Mahmuddin Mahmuddin ◽  
Dhian Ririn Lestari ◽  
Ichsan Rizani
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Side Effect ◽  
Life Quality ◽  
P Value ◽  
Symptom Scale ◽  
Cross Sectional ◽  
European Organization ◽  
The Mean

 Latar Belakang: Kanker payudara adalah keganasan sel yang menyerang payudara dan merupakan penyebab kematian kedua pada wanita. Frekuensi kemoterapi menimbulkan gangguan pada fungsi dan gejala kanker payudara yang dapat mempengaruhi kualitas hidup. Kualitas hidup merupakan keadaan yang menyatakan kepuasan batin dan kenyamanan hidup seseorang. Tujuan: Penelitian ini bertujuan untuk mengetahui hubungan lama menjalani kemoterapi dengan kualitas hidup penderita kanker payudara di RSUD Ulin Banjarmasin Metode: Penelitian ini merupakan penelitian analitik dengan pendekatan cross sectional menggunakan accidental sampling didapatkan 47 responden, penilaian kualitas hidup menggunakan European Organization of Research and Treatment of Cancer (EORTC) BR23. Uji Analisa menggunakan korelasi spearman. Hasil: Hasil rata-rata lama penderita menjalani kemoterapi sebanyak 4,53 kali  dan rata-rata kualitas hidup penderita kanker payudara berada di 65, 5% . Kesimpulan: dari Hasil analisis didapatkan ada hubungan antara lama menjalani kemoterapi dengan kualitas hidup penderita kanker payudara di RSUD Ulin Banjarmasin (P Value=0,000,01) dengan arah hubungan positif yakni semakin lama menjalani kemoterapi semakin tinggi nilai kualitas hidup penderita kanker payudara. Kualitas hidup yang paling tinggi dilihat dari function scale adalah sexs enjoyment yakni 72,0  sedangkan dari symptom scale   adalah side effect dengan skor 582,6 Kata kunci : kanker payudara, kemoterapi, kualitas hidup.Long Relationship Undergo Chemotherapy with Quality of Life of Breast Cancer Patients in Ulin Hospital BanjarmasinAbstractBackground: Breast cancer is a malignancy cells that attack breast and it is also the second leading cause of death among women. Frequency of chemotherapy may have detrimental function and symptom can make affect for patient’s quality of life. Quality of life is defined as condition to which individual reports inner satisfaction and comfort in life. Aim:The study to identify correlation between duration of chemotherapy and quality of life in patients with breast cancer RSUD Ulin Banjarmasin Method: This Research use Analitic Method with  design was cross sectional and involved 47 patients, all of whom were selected through accidental sampling. European Organization of Research and Treatment of Cancer (EORTC) BR23 was applied to measure patient’s quality of life. Anlyssis test using spearman correlation. Result: The mean of chemotherapy duration among participants was 4.53 times and the mean of QoL of patients with breast cancer was 73.31%. Conclusion: The analysis revealed a significant correlation between duration of chemotherapy and quality of life in patients with breast cancer in Ulin public hospital of Banjarmasin (p value = 0.000.01) with positive direction of association indicating that the longer the duration of make increase the score life quality of patients with breast cancer. The highest quality of life seen from the function scale is sex enjoyment, namely 72.0 while the symptom scale   is a side effect with a score of 582.6. Key words: breast cancer, chemotherapy, quality of life 

scholarly journals Survivourship Issues As Determinants of Quality of Life After Breast Cancer Treatment: Report From a Limited Resource Setting

2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 100s-100s
Author(s):  
N. Kaur ◽  
A. Gupta ◽  
A.K. Sharma
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Supportive Care ◽  
Cancer Survivors ◽  
Emotional Distress ◽  
Joint Pain ◽  
Breast Cancer Survivors ◽  
Breast Cancer Treatment

Background: Cancer survivorship is an unremitting struggle for breast cancer patients, as the consequence of complex treatment processes and its multitude of residual and late emerging side effects, have a significant impact on their quality of life (QOL). Unique issues of survivorship include those related to physical, psychological, social, and spiritual well-being of women. Amid a growing population of breast cancer survivors (BCs) worldwide, supportive care research is assuming greater importance in breast cancer care. Focus of survivorship research is to identify issues impacting QOL of the cancer survivors so that supportive care services can be tailored to their specific needs. Role of individual survivor's issues have been widely reported but a comprehensive picture is lacking. Aim: This study was conducted with the aim to identify important survivorship issues adversely affecting QOL of women after breast cancer treatment. Main objectives were to (1) estimate prevalence of various survivorship issues (2) assess QOL of survivors by using FACT-B and SF-36 questionnaires (3) study impact of time elapsed since treatment on survivorship issues and QOL scores (4) identify most important issues from the perspective of impact on QOL. Methods: This descriptive, hospital based, cross sectional study was conducted in 230 breast cancer survivors and a group of 112 healthy age-matched-controls, in an academic healthcare setting in northern India. A checklist of 14 commonly reported survivorship issues, and questionnaires for QOL assessment were administered to participants. Main outcome measures were (1) frequencies of survivorship issues and QOL scores among three groups divided on the basis of time elapsed since treatment (< 2 year follow-up, 2-5 year follow-up and > 5 year follow-up) (2) association of survivorship issues with QOL scores (3) stepwise regression analysis to identify issues with most significant impact on QOL of survivors. Results: Breast cancer survivors showed an improvement in their QOL over time which was sustained in long term survivors. However their quality of life remains poorer, compared with healthy women, irrespective of the duration of follow-up. The most prevalent survivorship issues were fatigue (60%), restriction of shoulder movement (59.6%), body and joint pain (63.5%), chemotherapy induced cessation of menstruation (73.3%) and loss of sexual desire (60%). However the issues which had maximum adverse effect on QOL scores were emotional distress, fatigue, postmastectomy chronic pain, cessation of menstruation, body and joint pain, vaginal dryness and sleep disturbances. Conclusion: Thus in this study, emotional distress and cancer related fatigue were found to be the chief determinants of poor QOL. Further premature menopause, with its attendant systemic symptoms, vulvo-vaginal atrophy and sexual dysfunction emerged as a key contributor to poor QOL in BCs.

scholarly journals Quality of Life of Breast Cancer Women During Chemotherapy with Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) Regimen

2017 ◽  
Vol 35 (4) ◽  
pp. 373
Author(s):  
Sophit Korpunsilp ◽  
Tipaporn Pongmesa
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Side Effects ◽  
Physical Functioning ◽  
P Value ◽  
Life Questionnaire ◽  
Appetite Loss ◽  
Eortc Qlq C30 ◽  
Eortc Qlq

Objective: To assess quality of life (QoL) of female breast cancer patients undergoing chemotherapy with a fluorouracil, doxorubicin, and cyclophosphamide (FAC) regimen.Material and Method: This prospective analytical study was performed among 40 Thai female patients receiving the FAC regimen at Pranangklao Hospital, Nonthaburi province. Their QoL was assessed using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and Breast Cancer Module (EORTC QLQ-BR23).Results: Most patients were aged 50 years or over (77.5%) and had been diagnosed with stage 2 breast cancer (47.5%). According to the EORTC QLQ-C30, the patients’ QoL significantly decreased compared to the baseline after cycle 3 for global health status (p-value=0.002) and QoL (p-value=0.001), as well as physical functioning (p-value=0.015) and role functioning (p-value=0.001), while symptoms of fatigue, nausea/vomiting, and appetite loss increased (p-value<0.001). After cycle 5, the patients’ QoL was still significantly lower than at baseline, for physical functioning (p-value=0.009) and symptoms of fatigue, nausea/vomiting, appetite loss (p-value<0.001) and dyspnea (p-value=0.005). The EORTC QLQ-BR23 reported significantly worse systemic therapy side effects for both cycles 3 and 5 (p-value<0.001), and distress due to hair loss also appeared after cycle 5 (p-value=0.016). No significant differences were revealed on any scales between cycles 3 and 5.Conclusion: The patients’ QoL significantly decreased after chemotherapy with the FAC regimen, with some side effects from treatment and reduction in some functioning.

Incidence of arthralgia syndrome (AS) related to aromatase inhibitors (AIs) in postmenopausal women with early breast cancer (EBC)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11603-e11603 ◽  
Author(s):  
R. Maisano ◽  
R. Maisano ◽  
D. Azzarello ◽  
P. Del Medico ◽  
R. Giannicola ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Joint Pain ◽  
Bone Fractures ◽  
Univariate Analysis ◽  
Joint Stiffness ◽  
Effective Therapy ◽  
Musculoskeletal Symptoms ◽  
Natural Menopause ◽  
Oral Supplements

e11603 Background: Anastozole (A) and letrozole (L) are standard drugs in up-front adjuvant endocrine therapy in postmenopausal hormone positive EBC. AIs have a higher incidence of osteoporosis, bone fractures and musculoskeletal symptoms, particularly joint pain and stiffness (AS) respect to tamoxifen. The real incidence of AS can be underestimated respect to data derived from clinical trials. Methods: From 1/07 to 12/07 we registered all patients (pts) taking A or L as adjuvant therapy for at least 3 months. We screened 47 pts, 3 pts refused to participate at the study and 2 resulted metastatic. A total of 42 pts were enrolled. The median age was 67 yrs (range 51–89), the median time since menopause was 11 yrs (range 1–48). 30 pts had natural menopause, 7 surgical menopause and 5 reported chemo-induced menopause. 25 pts took A and 17 pts took L. The median duration on therapy was 19 months (range 3–68) and 31 pts had received chemotherapy (9 CMF, 17 anthra-based, 5 anthra-taxane based). Results: 11 pts (26%) did not report AS, 19 pts (45%) had new-onset AS and 12 (29%) had worsening of prior joint pain after starting adjuvant AIs therapy. Most pts reported moderate to severe AS requiring occasional use of nonsteroidal anti-inflammatory drugs (75%), 15% used oral supplements and 10% used opiates, only 4 women used exercise to relieve joint stiffness. 17 pts interrupted the therapy from 7 to 20 days in order to reduce the symptoms and 7 obtained a partial improvement. 11 pts (35%) suffered from AS declared the worsening of quality of life. In univariate analysis presence of AS was not associated with age, entry into menopause, years since menopause, duration of AI therapy or previous chemotherapy. Conclusions: Our data show a higher incidence of AS in clinical practice respect to literature data, which caused worsening of quality of life and could be reason of discontinuation of effective therapy. The exact mechanism of AIs-related arthralgia is unclear, but is believed to be related to estrogen deprivation, however further studies are needed to define the pathogenesis in order to find an effective therapy. No significant financial relationships to disclose.

scholarly journals Social networks and quality of life among female breast cancer patients at Tikur Anbessa Specialzed Hospital, Addis Ababa, Ethiopia 2019

2019 ◽  
Author(s):  
Rahel Aberaraw(Former Corresponding Author) ◽  
Abdisa Boka ◽  
Roza Teshome ◽  
Addisu Yeshambel(New Corresponding Author)
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Social Networks ◽  
Cancer Patients ◽  
Addis Ababa ◽  
Female Breast Cancer ◽  
P Value ◽  
Breast Cancer Patients ◽  
Female Breast

Abstract Background : Breast cancer is a major life-threatening public health problem in the world. It is the most common form of cancer on females in many developing countries including Ethiopia. Social networks could change the course of cancer and can influence the quality of life among breast cancer patients. Therefore, the purpose of this study was to assess social networks and quality of life among female breast cancer patients attending in Tikur Anbassa Specialized Hospital, Addis Ababa, Ethiopia 2019. Methods : An institutional-based cross-sectional study was conducted in Tikur Anbessa Specialized Hospital Addis Ababa, Ethiopia from March to April 2019. A total of 214 female breast cancer patients were included and a systematic sampling method was used. A structured and pre-tested questionnaire was used. Data entry was done using epi data version 4.2. Data analysis was done using Statistical Package for the Social Sciences version 25. Binary and multiple logistic regression was used to show the association of social networks and quality of life. The strength of association was declared P-value <0.05 and 95%CI was used. Result: A total of 214 female with breast cancer were recruited with a mean age of 41.85. From participants, 13(6%), 65(30%) and 136(64%) had limited, medium and diverse social networks respectively. However, 198(92.52%) of them had affected the quality of life. It was found that participants who had children (AOR=5, 95%CL:1.3,21 COR=6), and other relatives(AOR=6, 95%CI: 1.2,30, COR=7), were more likely to have good social networks. In addition, it was found that participants who had systematic therapy side effects(AOR=3.8, 95%CI: 1.1,13, COR=4, p value=0.035), problem of appetite loss(AOR=3.5, 95%CI: 1.02,12 COR=4, p-value= 0.047) were more likely to have affected Quality of life. Conclusion: In this study finding, the quality of life and social networks on breast cancer females was relatively low. Healthcare providers especially working at the oncology department need to focus on addressing the side effects of therapy and social networks which may help to improve the quality of life of females with breast cancer.

scholarly journals Patient-reported outcomes version of the common terminology criteria for adverse events and quality-of-life linear analogue self-assessment in breast cancer patients receiving radiation therapy: single-institution prospective registry

2022 ◽  
Vol 6 (1) ◽  
Author(s):  
C. S. Thorpe ◽  
T. A. DeWees ◽  
M. A. Golafshar ◽  
R. S. Bhangoo ◽  
T. Z. Vern-Gross ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Patient Reported Outcomes ◽  
Self Assessment ◽  
Point Reduction ◽  
End Of Treatment ◽  
Patient Reported ◽  
The Common ◽  
Grade 3

Abstract Purpose/objectives We sought to investigate the impact of patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) on overall quality-of-life (QOL) employing linear analogue self-assessment (LASA) in breast cancer (BC) patients undergoing radiation therapy (RT). Materials/methods All patients treated with RT for BC with curative intent from 2015 to 2019 at our institution were included. Breast specific PRO-CTCAE and overall QOL LASA questionnaires were administered at baseline, end-of-treatment, 3, 6, 12 months, and then annually. Minimal clinically important difference in overall QOL was a 10-point change in LASA. Hypofractionation was any treatment > 2 Gy per fraction. Mixed models for repeated measures were used to determine the association of PRO-CTCAE and overall QOL LASA. Results Three hundred thirty-one (331) patients with a median follow-up of 3.1 years (range 0.4–4.9) were included. Average overall QOL LASA scores were 78.5 at baseline, 79.8 at end-of-treatment, 79.8 at 3 months, 77.1 at 6 months, 79.4 at 12 months, and 79.7 at 24 months. On univariate analysis, patients reporting a grade ≥ 3 PRO-CTCAE had, on average, a 10.4-point reduction in overall LASA QOL (p < 0.0001). On multivariate analysis, not being treated with hypofractionation and higher BMI were predictive for worse overall LASA QOL with a 10-point reduction in LASA for patients reporting a grade ≥ 3 PRO-CTCAE (p < 0.0001). Conclusions Patients reporting a grade ≥ 3 PRO-CTCAE experienced statistically significant and clinically meaningful deterioration in overall QOL LASA. Hypofractionation improved QOL while higher BMI predicted for worse QOL. PRO-CTCAE should be integrated into future clinical trials.

scholarly journals Physical Exercise with or without Whole-Body Vibration in Breast Cancer Patients Suffering from Aromatase Inhibitor—Induced Musculoskeletal Symptoms: A Pilot Randomized Clinical Study

2021 ◽  
Vol 11 (12) ◽  
pp. 1369
Author(s):  
Alessandro de Sire ◽  
Lorenzo Lippi ◽  
Antonio Ammendolia ◽  
Carlo Cisari ◽  
Konstantinos Venetis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Muscle Strength ◽  
Physical Exercise ◽  
Aromatase Inhibitor ◽  
Physical Performance ◽  
Whole Body Vibration ◽  
Musculoskeletal Symptoms ◽  
Whole Body

In this study, we aimed to assess the safety and efficacy of physical exercise, with or without whole-body vibration (WBV), in patients with aromatase inhibitor-induced musculoskeletal symptoms (AIMSS). Eligible patients were adults (≥18 years) with a history of breast cancer and current AIMSS. Enrolled patients (n = 22) were randomly assigned 1:1 to receive physical exercise combined with WBV or sham WBV for 4 weeks. The primary endpoint was pain intensity measured by numerical pain rating scale (NPRS). The secondary endpoints were muscle strength, physical function, physical performance, and quality of life. The WBV group (mean age: 51.73 ± 10.73 years; body mass index (BMI): 25.56 ± 5.17 kg/m2) showed a statistically significant pain reduction (NPRS: 6.82 ± 1.17 vs. 5.73 ± 1.01; p = 0.031), whereas patients in the sham WBV group (mean age: 58.55 ± 9.71 years; BMI: 27.31 ± 3.84 kg/m2), did not reach statistical significance (NPRS: 6.91 ± 2.02 vs. 5.91 ± 2.51; p = 0.07). Concurrently, muscle strength, physical performance, and quality of life significantly improved in both groups, without significant differences between groups. No dropouts and no side effects were recorded. Both patients and the physical therapist reported a high level of satisfaction with the intervention. Our findings suggest that physical exercise and WBV combination might be a safe therapeutic option for improving the rehabilitative management of patients with AIMSS.

Sign in / Sign up

Export Citation Format

Share Document